Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound
Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS ca...
Gespeichert in:
Veröffentlicht in: | Experimental neurology 2013-10, Vol.248, p.16-29 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 29 |
---|---|
container_issue | |
container_start_page | 16 |
container_title | Experimental neurology |
container_volume | 248 |
creator | Jordão, Jessica F. Thévenot, Emmanuel Markham-Coultes, Kelly Scarcelli, Tiffany Weng, Ying-Qi Xhima, Kristiana O'Reilly, Meaghan Huang, Yuexi McLaurin, JoAnne Hynynen, Kullervo Aubert, Isabelle |
description | Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS can deliver intravenously-administered antibodies to the brain of a mouse model of Alzheimer's disease (AD) and rapidly reduce plaques composed of amyloid-β peptides (Aβ). Here, we investigated two potential effects of transcranial FUS itself that could contribute to a reduction of plaque pathology, namely the delivery of endogenous antibodies to the brain and the activation of glial cells.
We demonstrate that transcranial FUS application leads to a significant reduction in plaque burden four days after a single treatment in the TgCRND8 mouse model of AD and that endogenous antibodies are found bound to Aβ plaques. Immunohistochemical and western blot analyses showed an increase in endogenous immunoglobulins within the FUS-targeted cortex. Subsequently, microglia and astrocytes in FUS-treated cortical regions show signs of activation through increases in protein expression and changes in glial size, without changes in glial cell numbers. Enhanced activation of glia correlated with increased internalization of Aβ in microglia and astrocytes.
Together these data demonstrate that FUS improved the bioavailability of endogenous antibodies and led to a temporal activation of glial cells, providing evidence towards antibody- and glia-dependent mechanisms of FUS-mediated plaque reduction.
•Focused ultrasound treatment reduces amyloid-β plaque pathology within 4days.•Host immunoglobulins enter the ultrasound-treated cortex where they bind to plaques.•Microglia and astrocyte markers are increased in the ultrasound-treated cortex.•Volumes of microglia and astrocytes are increased in the ultrasound-treated cortex.•Aβ within microglia and astrocytes is increased in the ultrasound-treated cortex. |
doi_str_mv | 10.1016/j.expneurol.2013.05.008 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4000699</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014488613001544</els_id><sourcerecordid>1432621371</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-284fa1dedc181d3f89e9c7a75cd06ad7ab4cc52586f7a295893e57fc2b89003f3</originalsourceid><addsrcrecordid>eNqFkc2O0zAUhS0EYsrAK4A3SCwm4dr5cbJBqkb8SSOxgbXl2DfFlWsXO6kmS16JB-GZcNVSYMXGlq6_e3x0DiEvGJQMWPt6W-L93uMcgys5sKqEpgToHpAVgx4KXlfwkKwAWF3UXddekScpbQGgr7l4TK54JUBUACvyfb1bXLCm-PmD7p36NiONaGY92eBvKHoTNujDnKjykx2CWahBZw8YlzwxdOOsclRl_KCOK3RY6BCV9cWk4gYnNDd0isonnY8jOgY9JzR0dnmcwuzNU_JoVC7hs_N9Tb68e_v59kNx9-n9x9v1XaEbaKaCd_WomEGjWcdMNXY99loo0WgDrTJCDbXWDW-6dhSK903XV9iIUfOh6wGqsbomb066-3nYZRn02YGT-2h3Ki4yKCv_ffH2q9yEg6xzbm3fZ4FXZ4EYck5pkjubNDqnPOaEJKsr3nJWCZZRcUJ1DClFHC_fMJDHAuVWXgqUxwIlNDIXmDef_-3ysve7sQy8PAMqaeXGnKu26Q8nhOhbqDO3PnGYMz1YjDJpi16jsRH1JE2w_zXzC6m9w7s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1432621371</pqid></control><display><type>article</type><title>Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Jordão, Jessica F. ; Thévenot, Emmanuel ; Markham-Coultes, Kelly ; Scarcelli, Tiffany ; Weng, Ying-Qi ; Xhima, Kristiana ; O'Reilly, Meaghan ; Huang, Yuexi ; McLaurin, JoAnne ; Hynynen, Kullervo ; Aubert, Isabelle</creator><creatorcontrib>Jordão, Jessica F. ; Thévenot, Emmanuel ; Markham-Coultes, Kelly ; Scarcelli, Tiffany ; Weng, Ying-Qi ; Xhima, Kristiana ; O'Reilly, Meaghan ; Huang, Yuexi ; McLaurin, JoAnne ; Hynynen, Kullervo ; Aubert, Isabelle</creatorcontrib><description>Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS can deliver intravenously-administered antibodies to the brain of a mouse model of Alzheimer's disease (AD) and rapidly reduce plaques composed of amyloid-β peptides (Aβ). Here, we investigated two potential effects of transcranial FUS itself that could contribute to a reduction of plaque pathology, namely the delivery of endogenous antibodies to the brain and the activation of glial cells.
We demonstrate that transcranial FUS application leads to a significant reduction in plaque burden four days after a single treatment in the TgCRND8 mouse model of AD and that endogenous antibodies are found bound to Aβ plaques. Immunohistochemical and western blot analyses showed an increase in endogenous immunoglobulins within the FUS-targeted cortex. Subsequently, microglia and astrocytes in FUS-treated cortical regions show signs of activation through increases in protein expression and changes in glial size, without changes in glial cell numbers. Enhanced activation of glia correlated with increased internalization of Aβ in microglia and astrocytes.
Together these data demonstrate that FUS improved the bioavailability of endogenous antibodies and led to a temporal activation of glial cells, providing evidence towards antibody- and glia-dependent mechanisms of FUS-mediated plaque reduction.
•Focused ultrasound treatment reduces amyloid-β plaque pathology within 4days.•Host immunoglobulins enter the ultrasound-treated cortex where they bind to plaques.•Microglia and astrocyte markers are increased in the ultrasound-treated cortex.•Volumes of microglia and astrocytes are increased in the ultrasound-treated cortex.•Aβ within microglia and astrocytes is increased in the ultrasound-treated cortex.</description><identifier>ISSN: 0014-4886</identifier><identifier>EISSN: 1090-2430</identifier><identifier>DOI: 10.1016/j.expneurol.2013.05.008</identifier><identifier>PMID: 23707300</identifier><identifier>CODEN: EXNEAC</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Alzheimer Disease - therapy ; Alzheimer's disease ; Amyloid beta-Peptides - genetics ; Amyloid beta-Peptides - metabolism ; Amyloid beta-Protein Precursor - genetics ; Amyloid beta-Protein Precursor - metabolism ; Amyloid-beta peptide ; Animals ; Astrocytes ; Autoantibodies ; Biological and medical sciences ; Blood-Brain Barrier - metabolism ; Blood-Brain Barrier - pathology ; Brain - metabolism ; Brain - pathology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Female ; Focused ultrasound ; Immunoglobulin ; Immunoglobulin G - metabolism ; Immunoglobulin M - metabolism ; Male ; Medical sciences ; Mice ; Mice, Transgenic ; Microglia ; Neuroglia - metabolism ; Neuroglia - pathology ; Neurology ; Plaque, Amyloid - genetics ; Plaque, Amyloid - metabolism ; Plaque, Amyloid - pathology ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Technology. Biomaterials. Equipments. Material. Instrumentation ; Transgenic mice ; Ultrasonography - methods</subject><ispartof>Experimental neurology, 2013-10, Vol.248, p.16-29</ispartof><rights>2013 Elsevier Inc.</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><rights>2013 Elsevier Inc. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-284fa1dedc181d3f89e9c7a75cd06ad7ab4cc52586f7a295893e57fc2b89003f3</citedby><cites>FETCH-LOGICAL-c505t-284fa1dedc181d3f89e9c7a75cd06ad7ab4cc52586f7a295893e57fc2b89003f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.expneurol.2013.05.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27779604$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23707300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jordão, Jessica F.</creatorcontrib><creatorcontrib>Thévenot, Emmanuel</creatorcontrib><creatorcontrib>Markham-Coultes, Kelly</creatorcontrib><creatorcontrib>Scarcelli, Tiffany</creatorcontrib><creatorcontrib>Weng, Ying-Qi</creatorcontrib><creatorcontrib>Xhima, Kristiana</creatorcontrib><creatorcontrib>O'Reilly, Meaghan</creatorcontrib><creatorcontrib>Huang, Yuexi</creatorcontrib><creatorcontrib>McLaurin, JoAnne</creatorcontrib><creatorcontrib>Hynynen, Kullervo</creatorcontrib><creatorcontrib>Aubert, Isabelle</creatorcontrib><title>Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound</title><title>Experimental neurology</title><addtitle>Exp Neurol</addtitle><description>Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS can deliver intravenously-administered antibodies to the brain of a mouse model of Alzheimer's disease (AD) and rapidly reduce plaques composed of amyloid-β peptides (Aβ). Here, we investigated two potential effects of transcranial FUS itself that could contribute to a reduction of plaque pathology, namely the delivery of endogenous antibodies to the brain and the activation of glial cells.
We demonstrate that transcranial FUS application leads to a significant reduction in plaque burden four days after a single treatment in the TgCRND8 mouse model of AD and that endogenous antibodies are found bound to Aβ plaques. Immunohistochemical and western blot analyses showed an increase in endogenous immunoglobulins within the FUS-targeted cortex. Subsequently, microglia and astrocytes in FUS-treated cortical regions show signs of activation through increases in protein expression and changes in glial size, without changes in glial cell numbers. Enhanced activation of glia correlated with increased internalization of Aβ in microglia and astrocytes.
Together these data demonstrate that FUS improved the bioavailability of endogenous antibodies and led to a temporal activation of glial cells, providing evidence towards antibody- and glia-dependent mechanisms of FUS-mediated plaque reduction.
•Focused ultrasound treatment reduces amyloid-β plaque pathology within 4days.•Host immunoglobulins enter the ultrasound-treated cortex where they bind to plaques.•Microglia and astrocyte markers are increased in the ultrasound-treated cortex.•Volumes of microglia and astrocytes are increased in the ultrasound-treated cortex.•Aβ within microglia and astrocytes is increased in the ultrasound-treated cortex.</description><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer Disease - therapy</subject><subject>Alzheimer's disease</subject><subject>Amyloid beta-Peptides - genetics</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Amyloid beta-Protein Precursor - genetics</subject><subject>Amyloid beta-Protein Precursor - metabolism</subject><subject>Amyloid-beta peptide</subject><subject>Animals</subject><subject>Astrocytes</subject><subject>Autoantibodies</subject><subject>Biological and medical sciences</subject><subject>Blood-Brain Barrier - metabolism</subject><subject>Blood-Brain Barrier - pathology</subject><subject>Brain - metabolism</subject><subject>Brain - pathology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Female</subject><subject>Focused ultrasound</subject><subject>Immunoglobulin</subject><subject>Immunoglobulin G - metabolism</subject><subject>Immunoglobulin M - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Microglia</subject><subject>Neuroglia - metabolism</subject><subject>Neuroglia - pathology</subject><subject>Neurology</subject><subject>Plaque, Amyloid - genetics</subject><subject>Plaque, Amyloid - metabolism</subject><subject>Plaque, Amyloid - pathology</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Technology. Biomaterials. Equipments. Material. Instrumentation</subject><subject>Transgenic mice</subject><subject>Ultrasonography - methods</subject><issn>0014-4886</issn><issn>1090-2430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2O0zAUhS0EYsrAK4A3SCwm4dr5cbJBqkb8SSOxgbXl2DfFlWsXO6kmS16JB-GZcNVSYMXGlq6_e3x0DiEvGJQMWPt6W-L93uMcgys5sKqEpgToHpAVgx4KXlfwkKwAWF3UXddekScpbQGgr7l4TK54JUBUACvyfb1bXLCm-PmD7p36NiONaGY92eBvKHoTNujDnKjykx2CWahBZw8YlzwxdOOsclRl_KCOK3RY6BCV9cWk4gYnNDd0isonnY8jOgY9JzR0dnmcwuzNU_JoVC7hs_N9Tb68e_v59kNx9-n9x9v1XaEbaKaCd_WomEGjWcdMNXY99loo0WgDrTJCDbXWDW-6dhSK903XV9iIUfOh6wGqsbomb066-3nYZRn02YGT-2h3Ki4yKCv_ffH2q9yEg6xzbm3fZ4FXZ4EYck5pkjubNDqnPOaEJKsr3nJWCZZRcUJ1DClFHC_fMJDHAuVWXgqUxwIlNDIXmDef_-3ysve7sQy8PAMqaeXGnKu26Q8nhOhbqDO3PnGYMz1YjDJpi16jsRH1JE2w_zXzC6m9w7s</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Jordão, Jessica F.</creator><creator>Thévenot, Emmanuel</creator><creator>Markham-Coultes, Kelly</creator><creator>Scarcelli, Tiffany</creator><creator>Weng, Ying-Qi</creator><creator>Xhima, Kristiana</creator><creator>O'Reilly, Meaghan</creator><creator>Huang, Yuexi</creator><creator>McLaurin, JoAnne</creator><creator>Hynynen, Kullervo</creator><creator>Aubert, Isabelle</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20131001</creationdate><title>Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound</title><author>Jordão, Jessica F. ; Thévenot, Emmanuel ; Markham-Coultes, Kelly ; Scarcelli, Tiffany ; Weng, Ying-Qi ; Xhima, Kristiana ; O'Reilly, Meaghan ; Huang, Yuexi ; McLaurin, JoAnne ; Hynynen, Kullervo ; Aubert, Isabelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-284fa1dedc181d3f89e9c7a75cd06ad7ab4cc52586f7a295893e57fc2b89003f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer Disease - therapy</topic><topic>Alzheimer's disease</topic><topic>Amyloid beta-Peptides - genetics</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Amyloid beta-Protein Precursor - genetics</topic><topic>Amyloid beta-Protein Precursor - metabolism</topic><topic>Amyloid-beta peptide</topic><topic>Animals</topic><topic>Astrocytes</topic><topic>Autoantibodies</topic><topic>Biological and medical sciences</topic><topic>Blood-Brain Barrier - metabolism</topic><topic>Blood-Brain Barrier - pathology</topic><topic>Brain - metabolism</topic><topic>Brain - pathology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Female</topic><topic>Focused ultrasound</topic><topic>Immunoglobulin</topic><topic>Immunoglobulin G - metabolism</topic><topic>Immunoglobulin M - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Microglia</topic><topic>Neuroglia - metabolism</topic><topic>Neuroglia - pathology</topic><topic>Neurology</topic><topic>Plaque, Amyloid - genetics</topic><topic>Plaque, Amyloid - metabolism</topic><topic>Plaque, Amyloid - pathology</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Technology. Biomaterials. Equipments. Material. Instrumentation</topic><topic>Transgenic mice</topic><topic>Ultrasonography - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jordão, Jessica F.</creatorcontrib><creatorcontrib>Thévenot, Emmanuel</creatorcontrib><creatorcontrib>Markham-Coultes, Kelly</creatorcontrib><creatorcontrib>Scarcelli, Tiffany</creatorcontrib><creatorcontrib>Weng, Ying-Qi</creatorcontrib><creatorcontrib>Xhima, Kristiana</creatorcontrib><creatorcontrib>O'Reilly, Meaghan</creatorcontrib><creatorcontrib>Huang, Yuexi</creatorcontrib><creatorcontrib>McLaurin, JoAnne</creatorcontrib><creatorcontrib>Hynynen, Kullervo</creatorcontrib><creatorcontrib>Aubert, Isabelle</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jordão, Jessica F.</au><au>Thévenot, Emmanuel</au><au>Markham-Coultes, Kelly</au><au>Scarcelli, Tiffany</au><au>Weng, Ying-Qi</au><au>Xhima, Kristiana</au><au>O'Reilly, Meaghan</au><au>Huang, Yuexi</au><au>McLaurin, JoAnne</au><au>Hynynen, Kullervo</au><au>Aubert, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound</atitle><jtitle>Experimental neurology</jtitle><addtitle>Exp Neurol</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>248</volume><spage>16</spage><epage>29</epage><pages>16-29</pages><issn>0014-4886</issn><eissn>1090-2430</eissn><coden>EXNEAC</coden><abstract>Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS can deliver intravenously-administered antibodies to the brain of a mouse model of Alzheimer's disease (AD) and rapidly reduce plaques composed of amyloid-β peptides (Aβ). Here, we investigated two potential effects of transcranial FUS itself that could contribute to a reduction of plaque pathology, namely the delivery of endogenous antibodies to the brain and the activation of glial cells.
We demonstrate that transcranial FUS application leads to a significant reduction in plaque burden four days after a single treatment in the TgCRND8 mouse model of AD and that endogenous antibodies are found bound to Aβ plaques. Immunohistochemical and western blot analyses showed an increase in endogenous immunoglobulins within the FUS-targeted cortex. Subsequently, microglia and astrocytes in FUS-treated cortical regions show signs of activation through increases in protein expression and changes in glial size, without changes in glial cell numbers. Enhanced activation of glia correlated with increased internalization of Aβ in microglia and astrocytes.
Together these data demonstrate that FUS improved the bioavailability of endogenous antibodies and led to a temporal activation of glial cells, providing evidence towards antibody- and glia-dependent mechanisms of FUS-mediated plaque reduction.
•Focused ultrasound treatment reduces amyloid-β plaque pathology within 4days.•Host immunoglobulins enter the ultrasound-treated cortex where they bind to plaques.•Microglia and astrocyte markers are increased in the ultrasound-treated cortex.•Volumes of microglia and astrocytes are increased in the ultrasound-treated cortex.•Aβ within microglia and astrocytes is increased in the ultrasound-treated cortex.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23707300</pmid><doi>10.1016/j.expneurol.2013.05.008</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-4886 |
ispartof | Experimental neurology, 2013-10, Vol.248, p.16-29 |
issn | 0014-4886 1090-2430 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4000699 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Alzheimer Disease - metabolism Alzheimer Disease - pathology Alzheimer Disease - therapy Alzheimer's disease Amyloid beta-Peptides - genetics Amyloid beta-Peptides - metabolism Amyloid beta-Protein Precursor - genetics Amyloid beta-Protein Precursor - metabolism Amyloid-beta peptide Animals Astrocytes Autoantibodies Biological and medical sciences Blood-Brain Barrier - metabolism Blood-Brain Barrier - pathology Brain - metabolism Brain - pathology Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Female Focused ultrasound Immunoglobulin Immunoglobulin G - metabolism Immunoglobulin M - metabolism Male Medical sciences Mice Mice, Transgenic Microglia Neuroglia - metabolism Neuroglia - pathology Neurology Plaque, Amyloid - genetics Plaque, Amyloid - metabolism Plaque, Amyloid - pathology Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Technology. Biomaterials. Equipments. Material. Instrumentation Transgenic mice Ultrasonography - methods |
title | Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T19%3A37%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amyloid-%CE%B2%20plaque%20reduction,%20endogenous%20antibody%20delivery%20and%20glial%20activation%20by%20brain-targeted,%20transcranial%20focused%20ultrasound&rft.jtitle=Experimental%20neurology&rft.au=Jord%C3%A3o,%20Jessica%20F.&rft.date=2013-10-01&rft.volume=248&rft.spage=16&rft.epage=29&rft.pages=16-29&rft.issn=0014-4886&rft.eissn=1090-2430&rft.coden=EXNEAC&rft_id=info:doi/10.1016/j.expneurol.2013.05.008&rft_dat=%3Cproquest_pubme%3E1432621371%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1432621371&rft_id=info:pmid/23707300&rft_els_id=S0014488613001544&rfr_iscdi=true |